Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial)
Latest Information Update: 30 Aug 2023
At a glance
- Drugs Lurbinectedin (Primary) ; Doxorubicin liposomal; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CORAIL
- Sponsors PharmaMar
- 28 Jul 2023 Results of pooled analysis from phase 2 basket and CORAIL trial safety data from several solid tumours treated at the lurbinectedin-approved dose published in the European Journal of Cancer.
- 06 Jun 2023 Results of post-hoc analysis of two studies CORAIL trial (NCT02421588) & NCT02454972 assessing safety analysis to evaluate lurbinectedin safety profile at the approved regimen (3.2 mg/m2 q3wk), presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 11 Sep 2021 Results published in the Gynecologic Oncology.